natgillin/translations-raw huggingface dataset:
While such increases may only be temporary, they could potentially lead to the withdrawal of those institutions as direct participants in those CCPs or to the, at least temporary, cessation of the provision of clearing services to those institutions' clients and thus cause disruption in the markets in which those CCPs operate and potentially in Union markets in general.
Od teh je bilo šest CNS iz Kanade, Mehike, Južne Afrike in Švice priznanih po sprejetju Izvedbene uredbe (EU) 2015/2326.
With regard to CCPs established in third countries that have applied for recognition so far, 17 CCPs have already been recognised by the European Securities and Markets Authority (ESMA).
Poleg tega se lahko CNS iz Južne Koreje in Združenih držav Amerike priznajo na podlagi izvedbenih sklepov Komisije (EU) 2015/2038 [7] oziroma (EU) 2016/377 [8].
Of those, 6 CCPs from Canada, Mexico, South Africa and Switzerland, have been recognised after the adoption of Implementing Regulation (EU) 2015/2326.
Potreba po preprečevanju motenj na trgih znotraj in zunaj Unije, ki je bila nazadnje razlog za podaljšanje prehodnega obdobja iz odstavkov 1 in 2 člena 497 Uredbe (EU) št. 575/2013, bi zato še naprej obstajala tudi po poteku podaljšanja prehodnega obdobja iz Izvedbene uredbe (EU) 2015/2326.
However, the remaining third-country CCPs are still awaiting recognition and the recognition process will not be completed by 15 June 2016.
Zato je primerno dodatno šestmesečno podaljšanje prehodnih obdobij.
The markets served by those remaining CCPs could also be severely disrupted in case the transitional period for institutions having exposures to those CCPs is not extended for the same reasons as in case of the non-extension of the transitional periods for CCPs established in the Union.
Ukrepi iz te uredbe so v skladu z mnenjem Evropskega odbora za bančništvo –
The need to avoid disruption to markets inside and outside of the Union that led previously to the extension of the transitional period laid down in paragraphs 1 and 2 of Article 497 of Regulation (EU) No 575/2013 would therefore remain after the expiry of the extension of the transitional period set out in Implementing Regulation (EU) 2015/2326.
SPREJELA NASLEDNJO UREDBO:
A further extension of the transitional period should enable institutions established in the Union (or their subsidiaries established outside the Union) to avoid significant increase in the own funds requirements due to the lack of completion of the authorisation or recognition processes for CCPs which provide, in a viable and accessible way, the specific type of clearing services that institutions established in the Union (or their subsidiaries established outside the Union) require.
Člen 1
An additional 6-month extension of the transitional periods is therefore appropriate.
esečna obdobja iz odstavkov 1 in 2 člena 497 Uredbe (EU) št. 575/2013 oziroma prvega in drugega pododstavka odstavka 5a člena 89 Uredbe (EU) št. 648/2012, ki so se že podaljšala v skladu s členom 1 izvedbenih uredb (EU) št. 591/2014, (EU) št. 1317/2014, (EU) 2015/880 in (EU) 2015/2326, se podaljšajo za dodatnih šest mesecev do 15. decembra 2016.
The measures provided for in this Regulation are in accordance with the opinion of the European Banking Committee,
Člen 2
The 15-month periods referred to in paragraphs 1 and 2 of Article 497 of Regulation (EU) No 575/2013 and in the first and second subparagraphs of paragraph 5a of Article 89 of Regulation (EU) No 648/2012, respectively, as extended pursuant to Article 1 of Implementing Regulations (EU) No 591/2014, (EU) No 1317/2014, (EU) 2015/880 and (EU) 2015/2326, are extended by an additional 6 months until 15 December 2016.
V Bruslju, 7. junija 2016
Done at Brussels, 7 June 2016.
Uredba (EU) št. 648/2012 Evropskega parlamenta in Sveta z dne 4. julija 2012 o izvedenih finančnih instrumentih OTC, centralnih nasprotnih strankah in repozitorijih sklenjenih poslov (UL L 201, 27.7.2012, str. 1).
For the Commission
Izvedbena uredba Komisije (EU) št. 591/2014 z dne 3. junija 2014 o podaljšanju prehodnih obdobij iz Uredbe (EU) št. 575/2013 in Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta v zvezi s kapitalskimi zahtevami za izpostavljenosti do centralnih nasprotnih strank (UL L 165, 4.6.2014, str. 31).
The President
Izvedbena uredba Komisije (EU) št. 1317/2014 z dne 11. decembra 2014 o podaljšanju prehodnih obdobij iz uredb (EU) št. 575/2013 in (EU) št. 648/2012 Evropskega parlamenta in Sveta v zvezi s kapitalskimi zahtevami za izpostavljenosti do centralnih nasprotnih strank (UL L 355, 12.12.2014, str. 6).
OJ L 176, 27.6.2013, p. 1.
Izvedbena uredba Komisije (EU) 2015/880 z dne 4. junija 2015 o podaljšanju prehodnih obdobij iz uredb (EU) št. 575/2013 in (EU) št. 648/2012 Evropskega parlamenta in Sveta v zvezi s kapitalskimi zahtevami za izpostavljenosti do centralnih nasprotnih strank (UL L 143, 9.6.2015, str. 7).
Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories (OJ L 201, 27.7.2012, p. 1).
Izvedbena uredba Komisije (EU) 2015/2326 z dne 11. decembra 2015 o podaljšanju prehodnih obdobij iz Uredbe (EU) št. 575/2013 in Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta v zvezi s kapitalskimi zahtevami za izpostavljenosti do centralnih nasprotnih strank (UL L 328, 12.12.2015, str. 108).
Commission Implementing Regulation (EU) No 591/2014 of 3 June 2014 on the extension of the transitional periods related to own funds requirements for exposures to central counterparties in Regulation (EU) No 575/2013 and Regulation (EU) No 648/2012 of the European Parliament and of the Council (OJ L 165, 4.6.2014, p. 31).
Izvedbeni sklep Komisije (EU) 2015/2038 z dne 13. novembra 2015 o enakovrednosti regulativnega okvira Republike Koreje za centralne nasprotne stranke zahtevam iz Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta o izvedenih finančnih instrumentih OTC, centralnih nasprotnih strankah in repozitorijih sklenjenih poslov (UL L 298, 14.11.2015, str. 25).
Commission Implementing Regulation (EU) No 1317/2014 of 11 December 2014 on the extension of the transitional periods related to own funds requirements for exposures to central counterparties in Regulations (EU) No 575/2013 and (EU) No 648/2012 of the European Parliament and of the Council (OJ L 355, 12.12.2014, p. 6).
Izvedbeni sklep Komisije (EU) 2016/377 z dne 15. marca 2016 o enakovrednosti regulativnega okvira Združenih držav Amerike za centralne nasprotne stranke, ki imajo dovoljenje Komisije za trgovanje z blagovnimi terminskimi pogodbami in so pod njenim nadzorom, zahtevam Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta (UL L 70, 16.3.2016, str. 32).
Commission Implementing Regulation (EU) 2015/880 of 4 June 2015 on the extension of the transitional periods related to own funds requirements for exposures to central counterparties set out in Regulations (EU) No 575/2013 and (EU) No 648/2012 of the European Parliament and of the Council (OJ L 143, 9.6.2015, p. 7).
Postopek za izdajo dovoljenja za obstoječe CNS v Uniji je v teku, vendar ne bo zaključen do 15. junija 2016.
Commission Implementing Regulation (EU) 2015/2326 of 11 December 2015 on the extension of the transitional periods related to own funds requirements for exposures to central counterparties set out in Regulation (EU) No 575/2013 and Regulation (EU) No 648/2012 of the European Parliament and of the Council (OJ L 328, 12.12.2015, p. 108).
Na izdajo dovoljenja čakata še dve CNS, ki imata sedež v Uniji.
Commission Implementing Decision (EU) 2015/2038 of 13 November 2015 on the equivalence of the regulatory framework of the Republic of Korea for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 25).
Vendar preostale CNS iz tretjih držav še vedno čakajo na priznanje, pri čemer postopek priznavanja ne bo zaključen do 15. junija 2016.
Commission Implementing Decision (EU) 2016/377 of 15 March 2016 on the equivalence of the regulatory framework of the United States of America for central counterparties that are authorised and supervised by the Commodity Futures Trading Commission to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council (OJ L 70, 16.3.2016, p. 32).
Na trgih, za katere opravljajo storitve navedene preostale CNS, bi lahko prav tako prišlo do resnih motenj, če prehodna obdobja za institucije, ki imajo izpostavljenosti do teh CNS, ne bi bila podaljšana, in sicer zaradi istih razlogov kot v primeru nepodaljšanja prehodnih obdobij za CNS s sedežem v Uniji.
Commission Implementing Regulation (EU) 2016/893
Izvedbena uredba Komisije (EU) 2016/893
Done at Brussels, 7 June 2016.
V Bruslju, 7. junija 2016
Commission Implementing Regulation (EU) 2016/895
Izvedbena uredba Komisije (EU) 2016/895
amending Regulation (EC) No 1290/2008 as regards the name of the holder of the authorisation of a preparation of Lactobacillus rhamnosus (CNCM-I-3698) and Lactobacillus farciminis (CNCM-I-3699)
o spremembi Uredbe (ES) št. 1290/2008 glede imena imetnika dovoljenja za pripravek Lactobacillus rhamnosus (CNCM-I-3698) in Lactobacillus farciminis (CNCM-I-3699)
Danisco (UK) Ltd has submitted an application in accordance with Article 13(3) of Regulation (EC) No 1831/2003 proposing to change the name of the holder of the authorisation as regards Commission Regulation (EC) No 1290/2008 [2] concerning the authorisation of a preparation of Lactobacillus rhamnosus (CNCM-I-3698) and Lactobacillus farciminis (CNCM- I-3699).
Družba Danisco (UK) Ltd. je predložila zahtevek v skladu s členom 13(3) Uredbe (ES) št. 1831/2003 s predlogom za spremembo imena imetnika dovoljenja iz Uredbe Komisije (ES) št. 1290/2008 [2] o izdaji dovoljenja za pripravek Lactobacillus rhamnosus (CNCM-I-3698) in Lactobacillus farciminis (CNCM-I-3699).
The applicant claims that, with effect from 12 November 2015, Danisco (UK) Ltd has transferred the marketing rights of the preparation of Lactobacillus rhamnosus (CNCM-I-3698) and Lactobacillus farciminis (CNCM- I-3699) to STI Biotechnologie.
Vložnik trdi, da je družba Danisco (UK) Ltd. z 12. novembrom 2015 prenesla pravice za trženje pripravka Lactobacillus rhamnosus (CNCM-I-3698) in Lactobacillus farciminis (CNCM-I-3699) na družbo STI Biotechnologie.
The proposed changes of the terms of the authorisation are purely administrative in nature and do not entail a fresh assessment of the additive concerned.
Predlagane spremembe pogojev dovoljenja so povsem upravnega značaja in ne vključujejo nove ocene zadevnega dodatka.
To allow that feed additive to be marketed under the name of STI Biotechnologie it is necessary to change the terms of the authorisation.
Da bi se omogočilo, da se krmni dodatek lahko trži pod imenom STI Biotechnologie, je treba spremeniti pogoje dovoljenja.
Regulation (EC) No 1290/2008 should therefore be amended accordingly.
Uredbo (ES) št. 1290/2008 bi zato bilo treba ustrezno spremeniti.
Since safety reasons do not require the immediate application of the amendment made by this Regulation to Regulation (EC) No 1290/2008, it is appropriate to provide for a transitional period during which existing stocks of the additive, premixtures and compound feed containing the additive may be used up.
Ker ni varnostnih razlogov, ki bi zahtevali takojšnjo uporabo spremembe Uredbe (ES) št. 1290/2008, uvedene s to uredbo, je ustrezno zagotoviti prehodno obdobje, v katerem se lahko porabijo obstoječe zaloge dodatkov ter premiksov in krmnih mešanic, ki vsebujejo dodatek.
In the Annex to Regulation (EC) No 1290/2008, in the second column, the words ‘Danisco (UK) Ltd’ are replaced by ‘STI Biotechnologie’.
V Prilogi k Uredbi (ES) št. 1290/2008 se v drugem stolpcu besedna zveza „Danisco (UK) Ltd.“ nadomesti s „STI Biotechnologie“.
Existing stocks of the additive, premixtures and compound feed containing the additive, which are in conformity with the provisions applying before the date of entry into force of this Regulation may continue to be placed on the market and used until they are exhausted.
Obstoječe zaloge dodatka ter premiksov in krmnih mešanic, ki vsebujejo dodatek, ki so skladne z določbami, ki so se uporabljale pred začetkom veljavnosti te uredbe, se lahko še naprej dajejo na trg in uporabljajo, dokler se ne porabijo.
Commission Regulation (EC) No 1290/2008 of 18 December 2008 concerning the authorisation of a preparation of Lactobacillus rhamnosus (CNCM-I-3698) and Lactobacillus farciminis (CNCM-I-3699) as a feed additive (OJ L 340, 19.12.2008, p. 20).
Uredba Komisije (ES) št. 1290/2008 z dne 18. decembra 2008 o izdaji dovoljenja za pripravek Lactobacillus rhamnosus (CNCM-I-3698) in Lactobacillus farciminis (CNCM-I-3699) kot krmni dodatek (UL L 340, 19.12.2008, str. 20).
Commission Implementing Regulation (EU) 2016/896
Izvedbena uredba Komisije (EU) 2016/896
concerning the authorisation of iron sodium tartrates as a feed additive for all animal species
o izdaji dovoljenja za železove natrijeve tartrate kot krmni dodatek za vse živalske vrste
In accordance with Article 7 of Regulation (EC) No 1831/2003 an application was submitted for the authorisation of iron sodium tartrates.
Zahtevek za izdajo dovoljenja za železove natrijeve tartrate je bil predložen v skladu s členom 7 Uredbe (ES) št. 1831/2003.
That application concerns the authorisation of iron sodium tartrates as a feed additive for all animal species, to be classified in the additive category ‘technological additives’.
Navedeni zahtevek zadeva dovoljenje za uvrstitev železovih natrijevih tartratov kot krmnega dodatka za vse živalske vrste v kategorijo dodatkov „tehnološki dodatki“.
The European Food Safety Authority (‘the Authority’) concluded in its opinion of 30 April 2015 [2] that, under the proposed conditions of use, the preparation concerned does not have an adverse effect on animal health, human health or the environment.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v mnenju z dne 30. aprila 2015 [2] navedla, da zadevni pripravek pod predlaganimi pogoji uporabe nima škodljivega vpliva na zdravje živali in ljudi ali na okolje.
The Authority also concluded that the preparation has the potential to be efficacious as an anti-caking agent in salt.
Poleg tega je Agencija navedla, da je pripravek lahko učinkovit kot sredstvo proti strjevanju v soli.
The Authority does not consider that there is a need for specific requirements of post-market monitoring.
Agencija meni, da ni potrebe po posebnih zahtevah glede spremljanja po dajanju na trg.
It also verified the report on the methods of analysis of the feed additive in feed submitted by the Reference Laboratory set up by Regulation (EC) No 1831/2003.
Potrdila je tudi poročilo o analitskih metodah krmnega dodatka v krmi, ki jih je predložil referenčni laboratorij, ustanovljen z Uredbo (ES) št. 1831/2003.
The assessment of iron sodium tartrates shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Ocena železovih natrijevih tartratov je pokazala, da so pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003 izpolnjeni.
The preparation specified in the Annex, belonging to the additive category ‘technological additives’ and to the functional group ‘anti-caking agents’ is authorised as an additive in animal nutrition, subject to the conditions laid down in that Annex.
Pripravek iz Priloge, ki spada v kategorijo dodatkov „tehnološki dodatki“ in funkcionalno skupino „sredstva proti strjevanju“, se dovoli kot dodatek v prehrani živali v skladu s pogoji iz navedene priloge.
Composition, chemical formula, description, methods of analysis
Sestava, kemijska formula, opis, analitska metoda
End of period of authorisation
Datum poteka veljavnosti dovoljenja
mg of active substance/kg of NaCl
mg aktivne snovi/kg NaCl
Technological additives: anti-caking agents
Tehnološki dodatki: sredstva proti strjevanju
Iron sodium tartrates
železovi natrijevi tartrati
Preparation of complexation products of sodium tartrates with iron(III) chloride in water solution ≤ 35 % (by weight).
Pripravek kompleksov natrijevih tartratov z železovim(III) kloridom v raztopini vode ≤ 35 % (po teži).
Iron(III) complexation product of D(+)-, L(-)- and meso-2,3-dihydroxybutanedioic acids
železov(III) kompleks D(+)-, L(–)- in mezo-2,3-dihidroksibutandiojskih kislin
Ratio: iron to meso-tartrate 1:1;
Razmerje: železo proti mezo-tartrat: 1:1
Ratio: iron to total tartrate isomers 1:1,5
Razmerje: železo proti skupnim izomerom tartrata: 1:1,5
CAS number 1280193-05-9
Št.
Chloride: ≤ 25 %
CAS 1280193-05-9
Oxalates: ≤ 1,5 % expressed as oxalic acid
Klorid: ≤ 25 %
Iron: ≥ 8 % iron(III)
Oksalati: ≤ 1,5 %, izraženi kot oksalna kislina
Analytical method [1]Quantification of meso-tartrate and D(-), L(+)-tartrates in the feed additive:
Železo: ≥ 8 % trivalentnega železa
High Performance Liquid Chromatography with Refraction Index detection (HPLC-RI);
Analitska metoda [1]Količinska opredelitev mezo-tartrata in D(–), L(+) -tartratov v krmnem dodatku:
Quantification of total iron in the feed additive:
tekočinska kromatografija visoke ločljivosti z detekcijo na osnovi lomnega količnika (HPLC-RI);
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) — EN 15510, or
Količinska opredelitev skupnega železa v krmnem dodatku:
Inductively Coupled Plasma Atomic Emission Spectroscopy after pressure digestion (ICP-AES) — EN 15621,or
atomska emisijska spektroskopija z induktivno sklopljeno plazmo (ICP-AES) – EN 15510; ali
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) — EN ISO 11885, or
atomska emisijska spektroskopija z induktivno sklopljeno plazmo po razklopu pod tlakom (ICP-AES) – EN 15621; ali
Atomic Absorption Spectrometry (AAS) — EN ISO 6869, or
atomska emisijska spektroskopija z induktivno sklopljeno plazmo (ICP-AES) – EN ISO 11885; ali
Atomic Absorption Spectrometry (AAS) — Commission Regulation (EC) No 152/2009 [2]; and
atomska absorpcijska spektrometrija (AAS) – EN ISO 6869; ali
Quantification of total sodium in the feed additive:
atomska absorpcijska spektrometrija (AAS) – Uredba Komisije (ES) št. 152/2009 [2]; ter
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) — EN 15510; or
Količinska opredelitev skupnega natrija v krmnem dodatku:
Inductively Coupled Plasma Atomic Emission Spectroscopy after pressure digestion (ICP-AES) — EN 15621; or
atomska emisijska spektroskopija z induktivno sklopljeno plazmo (ICP-AES) – EN 15510; ali
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) — EN ISO 11885; or
atomska emisijska spektroskopija z induktivno sklopljeno plazmo po razklopu pod tlakom (ICP-AES) – EN 15621; ali
Atomic Absorption Spectrometry (AAS) — EN ISO 6869; and
atomska emisijska spektroskopija z induktivno sklopljeno plazmo (ICP-AES) – EN ISO 11885; ali
Quantification of total chloride in the feed additive:
atomska absorpcijska spektrometrija (AAS) – EN ISO 6869; ter
Titrimetry —Regulation (EC) No 152/2009 or ISO 6495.
Količinska opredelitev skupnega klorida v krmnem dodatku:
All animals species
titrimetrija – Uredba (ES) št. 152/2009 ali ISO 6495.
The additive shall be used only in NaCl (sodium chloride).
vse živalske vrste
Minimum recommended dose: 26 mg of iron sodium tartrates/kg NaCl (equivalent to 3 mg iron/kg of NaCl).
Dodatek se uporablja le v NaCl (natrijev klorid).
Maximum recommended dose: 106 mg of iron sodium tartrates/kg NaCl.
Najnižji priporočeni odmerek: 26 mg železovih natrijevih tartratov/kg NaCl (kar je enako 3 mg železa na kg NaCl)
29 June 2026
Najvišji priporočeni odmerek: 106 mg železovih natrijevih tartratov na kg NaCl
Details of the analytical methods are available at the following address of the Reference Laboratory: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports
29. junij 2026
Commission Regulation (EC) No 152/2009 of 27 January 2009 laying down the methods of sampling and analysis for the official control of feed (OJ L 54, 26.2.2009, p.
Podrobnosti o analitskih metodah so na voljo na naslovu referenčnega laboratorija: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports.
Commission Implementing Regulation (EU) 2016/897
Izvedbena uredba Komisije (EU) 2016/897
concerning the authorisation of a preparation of Bacillus subtilis (C-3102) (DSM 15544) as a feed additive for laying hens and ornamental fish (holder of authorisation Asahi Calpis Wellness Co.
o izdaji dovoljenja za pripravek iz Bacillus subtilis (C-3102) (DSM 15544) kot krmni dodatek za kokoši nesnice in okrasne ribe (imetnik dovoljenja Asahi Calpis Wellness Co.
Ltd) and amending Regulations (EC) No 1444/2006, (EU) No 333/2010 and (EU) No 184/2011 as regards the holder of the authorisation
Ltd.) in o spremembi uredb (ES) št. 1444/2006, (EU) št. 333/2010 in (EU) št. 184/2011, kar se tiče imetnika dovoljenja
Having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition [1], and in particular Article 9(2) and Article 13(3) thereof,
ob upoštevanju Uredbe Evropskega parlamenta in Sveta (ES) št. 1831/2003 z dne 22. septembra 2003 o dodatkih za uporabo v prehrani živali [1] in zlasti členov 9(2) in 13(3) Uredbe,
In accordance with Article 7 of Regulation (EC) No 1831/2003 applications were submitted for the authorisation of a preparation of Bacillus subtilis (C-3102).
V skladu s členom 7 Uredbe (ES) št. 1831/2003 so bili vloženi zahtevki za izdajo dovoljenja za pripravek iz Bacillus subtilis (C-3102).
Those applications concern the authorisation of a preparation of Bacillus subtilis (C-3102) as a feed additive for all laying birds and ornamental fish to be classified in the additive category ‘zootechnical additives’.
Navedeni zahtevki zadevajo izdajo dovoljenja za pripravek iz Bacillus subtilis (C-3102) kot krmni dodatek za vse nesnice in okrasne ribe ter njegovo uvrstitev v kategorijo dodatkov „zootehnični dodatki“.
That preparation was already authorised as a feed additive for use in chickens for fattening by Commission Regulation (EC) No 1444/2006 [2] in piglets by Commission Regulation (EU) No 333/2010 [3], and in chickens reared for laying and turkeys, minor avian species and other ornamental and game birds by Commission Regulation (EU) No 184/2011 [4].
Navedeni pripravek je bil že odobren kot krmni dodatek za piščance za pitanje z Uredbo Komisije (ES) št. 1444/2006 [2], za pujske z Uredbo Komisije (EU) št. 333/2010 [3] ter za piščance za nesnice, purane, manj pomembne vrste ptic ter druge okrasne in divje ptice z Uredbo Komisije (EU) št. 184/2011 [4].
The European Food Safety Authority (‘the Authority’) concluded in its opinions of 28 September 2015 [5] and of 11 November 2015 [6] that, under the proposed conditions of use, the preparation of Bacillus subtilis (C-3102) is presumed not to have an adverse effect on animal health, human health or the environment.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v mnenjih z dne 28. septembra 2015 [5] in z dne 11. novembra 2015 [6] ugotovila, da pripravek iz Bacillus subtilis (C-3102) pod predlaganimi pogoji uporabe predvidoma nima škodljivega vpliva na zdravje živali in ljudi ter na okolje.
It concluded that, under the proposed condition of use, the additive has the potential to be efficacious in reducing the amount of feed per unit of mass egg production over the entire laying period.
Ugotovila je, da je dodatek pod predlaganimi pogoji uporabe lahko učinkovit pri zmanjševanju količine krme, potrebne za proizvodnjo enega kilograma jajc v celotnem valilnem obdobju.
The Authority also concluded that the additive has the potential to improve the grow and feed utilisation in ornamental fish.
Agencija je tudi ugotovila, da lahko dodatek izboljša rast okrasnih rib in uporabo krme zanje.
The assessment of the preparation of Bacillus subtilis (C-3102) shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Ocena pripravka Bacillus subtilis (C-3102) je pokazala, da so izpolnjeni pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003.